Sanofi launches its $3.68 billion offer for Principia Biopharma
PARIS (Reuters) – Sanofi announced Friday the launch of its tender offer to acquire Principia Biopharma, a U.S. biotech company specializing in the development of treatments for autoimmune and allergic diseases, which will strengthen its portfolio in immunology.
The transaction, through a repurchase of all outstanding shares at a price of $100 per share, represents a cash transaction valued at approximately $3.68 billion ('3.1 billion) and is expected to close in the fourth quarter of 2020.
The offer, which closed on August 16, will expire on September 25.
Claude Chendjou
Facebook
Twitter
LinkedIn
Pinterest

Advertisement
Articles récents
- Swiss approve of Israeli artificial meats 30 August 2023
- “Barbie” film, an outstanding success in China 29 August 2023
- Is Elon Musk racist? 27 August 2023
- FC Cincinnati vs. Inter Miami What to Expect! 23 August 2023
- Cruise cabs in the authorities’ sights 23 August 2023
Recent Posts
- Swiss approve of Israeli artificial meats 30 August 2023
- “Barbie” film, an outstanding success in China 29 August 2023
- Is Elon Musk racist? 27 August 2023
- FC Cincinnati vs. Inter Miami What to Expect! 23 August 2023
- Cruise cabs in the authorities’ sights 23 August 2023

Advertisement

Advertisement
Follow us on Instagram!
Suis nous sur instagram!
Starbucks

Advertisment
Recent Posts
- Swiss approve of Israeli artificial meats 30 August 2023
- “Barbie” film, an outstanding success in China 29 August 2023
- Is Elon Musk racist? 27 August 2023
- FC Cincinnati vs. Inter Miami What to Expect! 23 August 2023
- Cruise cabs in the authorities’ sights 23 August 2023
Articles Recents
- Swiss approve of Israeli artificial meats 30 August 2023
- “Barbie” film, an outstanding success in China 29 August 2023
- Is Elon Musk racist? 27 August 2023
- FC Cincinnati vs. Inter Miami What to Expect! 23 August 2023
- Cruise cabs in the authorities’ sights 23 August 2023